for the purpose of incorporating the information set forth herein by reference into the automatic shelf registration statement on Form S-3ASR (File No. 333-198598) that was filed by the registrant with the Securities and
Friday, August 21, 2015 BiopharmaWatch Research 1 min read
Key Takeaway: The registrant is filing this
Exchange Commission on September 5, 2014.
The following table sets forth the estimated costs and expenses, other than underwriting discounts and
commissions, payable by the registrant in connection with the sale of the securities being registered:
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
AG019- Low Dose
Phase 1 · Diabetes type1
Full Press Release Details
The registrant is filing this
Exchange Commission on September 5, 2014.
The following table sets forth the estimated costs and expenses, other than underwriting discounts and
commissions, payable by the registrant in connection with the sale of the securities being registered: